Warning! GuruFocus detected
1 Severe warning sign
with ELEV.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Elevation Oncology Inc
NAICS : 541713
SIC : 2834
ISIN : US28623U1016
Description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.99 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | -0.77 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.6 | |||||
| 3-Year EPS without NRI Growth Rate | 33.8 | |||||
| 3-Year FCF Growth Rate | 36.6 | |||||
| 3-Year Book Growth Rate | -44.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.72 | |||||
| 9-Day RSI | 56.21 | |||||
| 14-Day RSI | 51.11 | |||||
| 3-1 Month Momentum % | -57.07 | |||||
| 6-1 Month Momentum % | -56.35 | |||||
| 12-1 Month Momentum % | -92.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.21 | |||||
| Quick Ratio | 21.21 | |||||
| Cash Ratio | 20.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.6 | |||||
| Shareholder Yield % | -203.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -65.24 | |||||
| ROA % | -43.22 | |||||
| ROIC % | -1452.43 | |||||
| 3-Year ROIIC % | -621.11 | |||||
| ROC (Joel Greenblatt) % | -8287.3 | |||||
| ROCE % | -40.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.35 | |||||
| Price-to-Tangible-Book | 0.35 | |||||
| EV-to-EBIT | 0.98 | |||||
| EV-to-EBITDA | 0.98 | |||||
| EV-to-FCF | 1.09 | |||||
| Price-to-Net-Current-Asset-Value | 0.36 | |||||
| Price-to-Net-Cash | 0.37 | |||||
| Earnings Yield (Greenblatt) % | 102.04 | |||||
| FCF Yield % | -172.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELEV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elevation Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.81 | ||
| Beta | 1.48 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.95 | ||
| Volatility % | 94.64 | ||
| 14-Day RSI | 51.11 | ||
| 14-Day ATR ($) | 0.036959 | ||
| 20-Day SMA ($) | 0.306125 | ||
| 12-1 Month Momentum % | -92.82 | ||
| 52-Week Range ($) | 0.221 - 4.48 | ||
| Shares Outstanding (Mil) | 59.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elevation Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elevation Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Elevation Oncology Inc Frequently Asked Questions
What is Elevation Oncology Inc(ELEV)'s stock price today?
The current price of ELEV is $0.36. The 52 week high of ELEV is $4.48 and 52 week low is $0.22.
When is next earnings date of Elevation Oncology Inc(ELEV)?
The next earnings date of Elevation Oncology Inc(ELEV) is 2025-05-02 Est..
Does Elevation Oncology Inc(ELEV) pay dividends? If so, how much?
Elevation Oncology Inc(ELEV) does not pay dividend.
Guru Commentaries on NAS:ELEV
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers